As of Q2 2024, Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Candel’s enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

CAN-2409 is Candel's lead product candidate and is ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase II), borderline resectable PDAC (phase II), and localized, non-metastatic prostate cancer (phase II and phase III).